Pan et al. demonstrated the predictive role of complement C3 as a candidate biomarker for diagnosing NAFLD in chronic kidney disease (CKD) patients at the best cut-off value of 993.5 mg/L for complement C3 with a sensitivity of 63.9% and a specificity of 70.1% (17). This evidence concerns the gene C3 and metabolic dysfunction-associated steatotic liver disease.